Diego A. Díaz García, Medical Oncologist / CEO / Founder at CánCare – Advanced Specialty in Oncology, shared on X:
“Next-gen targeted therapies are reshaping frontline treatment in metastatic NSCLC.
Improved CNS penetration
Better resistance profiles
Enhanced selectivity = more efficacy, less toxicity
The future? Smarter combinations and biomarker-driven strategies.”
Title: Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer
Authors: Sarah Waliany, Jessica J. Lin, Justin F. Gainor
Read the Full Article.
More posts featuring Diego Díaz García.
